Art

J-GLOBAL ID：201902218213021687   Reference number：19A0714745

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

切除不能局所進行膵臓癌に対する腫瘍溶解性ウイルスHF10のEUS誘導腫瘍内注射の第I相臨床試験【JST・京大機械翻訳】

Author (12)： Hirooka Yoshiki (Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan) ,  Kasuya Hideki (Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Ishikawa Takuya (Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Kawashima Hiroki (Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Ohno Eizaburo (Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Villalobos Itzel B. (Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Naoe Yoshinori (Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Ichinose Toru (Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Koyama Nobuto (Takara Bio Inc., Otsu, Japan) ,  Tanaka Maki (Takara Bio Inc., Otsu, Japan) ,  Kodera Yasuhiro (Department of Surgery II, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Goto Hidemi (Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
Material： BMC Cancer (Web)
Volume： 18  Issue： 1  Page： 596  Publication year： 2018 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Prognosis of pancreatic cancer...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0714745&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： drug therapy ,  pancreatic tumor ,  human ,  combination therapy ,  *tumor ,  Safety ,  Prognosis ,  antitumor action ,  end point ,  Research Subjects ,  adverse reaction ,  halogeno sugar ,  deoxyribonucleoside ,  enzyme inhibitor
Semi thesaurus term： 進行性疾患 ,  有害事象 ,  悪性腫瘍 ,  *局所進行膵癌 , 【Automatic Indexing@JST】

Author keywords (4)： Pancreatic cancer ,  Oncolytic virus ,  HF10 ,  EUS-guidance

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of digestive system  (GH04000D)

Substance index (2)： Gemcitabine ,  Erlotinib

Reference (38)：

• CA Cancer J Clin; Cancer statistics, 2016; RL Siegel, KD Miller, A Jemal; 66; 1; 2016; 7-30; 10.3322/caac.21332; citation_id=CR1
• Jpn J Clin Oncol; Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis; J Furuse, A Gemma, W Ichikawa, T Okusaka, A Seki, T Ishii; 47; 9; 2017; 1-8; 10.1093/jjco/hyx075; citation_id=CR2
• J Am Coll Surg; Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database; SF Sener, A Fremgen, HR Menck, DP Winchester; 189; 1; 1999; 1-7; 10.1016/S1072-7515(99)00075-7; citation_id=CR3
• Expert Rev Anticancer Ther; Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions; S Myrehaug, A Sahgal, SM Russo, SS Lo, LM Rosati, NA Mayr, M Lock, W Small, JA Dorth, RJ Ellis; 16; 5; 2016; 523-530; 10.1586/14737140.2016.1168698; citation_id=CR4
• Front Oncol; Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials; IR Eissa, Y Naoe, I Bustos-Villalobos, T Ichinose, M Tanaka, W Zhiwen, N Mukoyama, T Morimoto, N Miyajima, H Hitoki; 7; 2017; 149; 10.3389/fonc.2017.00149; citation_id=CR5

Terms in the title (10)： 切除不能 ,  局所進行膵臓癌 ,  腫瘍溶解性ウイルス ,  HF10 ,  EUS ,  誘導 ,  腫瘍 ,  注射 ,  I相 ,  臨床試験